Mateon Therapeutics (OTCMKTS:MATN) Stock Crosses Above Two Hundred Day Moving Average of $0.03

Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATNGet Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 154,410 shares trading hands.

Mateon Therapeutics Stock Up 35.8 %

The company has a fifty day moving average price of $0.03 and a 200-day moving average price of $0.03.

About Mateon Therapeutics

(Get Free Report)

Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.

Recommended Stories

Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with's FREE daily email newsletter.